Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

1
results for

"Su Hyeon Jeong"

Keywords

Publication year

"Su Hyeon Jeong"

Original Article

Viral hepatitis

Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience
Eun Ju Cho, Su Hyeon Jeong, Byung Hoon Han, Sang Uk Lee, Byung Chul Yun, Eun Taek Park
Korean J Hepatol 2012;18(2):219-224.
Published online June 26, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.2.219
Background/Aims

There is some controversy regarding whether or not hepatitis C virus (HCV) subtype 1b is more influential than non-1b subtypes on the progression of chronic hepatitis (CH) C to liver cirrhosis (LC) and hepatocellular carcinoma (HCC).

Methods

We retrospectively analyzed 823 patients with chronic HCV infection, including 443 CH patients, 264 LC patients, and 116 HCC patients, who were HCV RNA positive and HBsAg negative. These patients had not received any prior treatment with either interferon alone or a combination of interferon and ribavirin.

Results

HCV subtypes 1b (51.6%) and 2a/2c (39.5%) were the two most common genotypes. The proportions of genotypes 2 (2a/2c, 2b, and 2) and 3 were 45.8% and 1.1%, respectively. One case of genotype 4 was found. HCV subtype 1b (47.3%) was less common than the non-1b subtypes (52.7%) in non-LC patients, but its proportion (56.9%) was higher than that of non-1b subtypes (43.1%) in LC patients (P=0.006). The proportions of patients with HCV subtype 1b did not differ significantly between the LC (55.3%) and HCC (60.3%) groups. Older age, male gender, and the relative progression of liver damage (non-LC vs. compensated LC vs. decompensated LC) were significant risk factors for HCC, with odds ratios of 1.081 (95% confidence interval [CI], 1.056-1.106), 5.749 (95% CI, 3.329-9.930), and 2.895 (95% CI, 2.183-3.840), respectively. HCV subtype 1b was not a significant risk factor for HCC (odds ratio, 1.423; 95% CI, 0.895-2.262).

Conclusions

HCV subtypes 1b and 2a/2c were the two most common HCV genotypes. HCV subtype 1b seemed to be more influential than non-1b subtypes on the progression of CH to LC, but not on the development of HCC from LC.

Citations

Citations to this article as recorded by  Crossref logo
  • 2025 KASL clinical practice guidelines for management of hepatitis C
    Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung
    Clinical and Molecular Hepatology.2026; 32(1): 1.     CrossRef
  • Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C
    Jin-Woo Lee, Sang Hoon Ahn, Jeong Gil Park, Jae Youn Jeong, Ki Tae Yoon, Won Young Tak, Yang Hyun Baek, Su Jong Yu, Myeong Jun Song, Yeon Seok Seo, Ji Young Jeong, Jeong Heo
    Infectious Diseases and Therapy.2026; 15(6): 1747.     CrossRef
  • Molecular Epidemiology of Hepatitis C Virus Genotypes in Northern Thailand: A Retrospective Study from 2016 to 2024
    Nang Kham-Kjing, Sirithip Phruekthayanon, Thipsuda Krueyot, Panaddar Phutthakham, Sorasak Intarasoot, Khajornsak Tragoolpua, Kanya Preechasuth, Tanawan Samleerat Carraway, Natedao Kongyai, Woottichai Khamduang
    Infectious Disease Reports.2025; 17(4): 73.     CrossRef
  • Epidemiology and Management of Hepatitis C in Korea
    Jaeyoun Cheong
    Korean Journal of Healthcare-Associated Infection Control and Prevention.2025; 30(2): 118.     CrossRef
  • Hepatitis C viral load and genotypes distribution among chronically infected patients in Morocco
    Samia Boukaira, Salma Madihi, Warda Baha, Bouchra Belkadi, Abdelouaheb Benani
    Gene Reports.2024; 34: 101874.     CrossRef
  • Hepatitis C virus among blood donors in Lubumbashi, DRC: Seroprevalence and molecular characterisation
    A. Kabamba-Tshikongo, H. Manya-Mboni, C. Mwamba-Mulumba, N.B. Takaisi-Kikuni, A.T. Vandenbroucke, A.T. Pâques, G. Dessilly, B. Kabamba-Mukadi, A. Longanga-Otshudi
    Transfusion Clinique et Biologique.2023; 30(2): 272.     CrossRef
  • Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study
    Ik Sung Choi, Kwang Min Kim, Sang Goon Shim
    Arab Journal of Gastroenterology.2021; 22(1): 23.     CrossRef
  • A Healthcare-Associated Outbreak of HCV Genotype 2a at a Clinic in Seoul
    Siwon Choi, Hyerim Lee, Hyungmin Lee, Yoon-Seok Chung
    Osong Public Health and Research Perspectives.2021; 12(1): 3.     CrossRef
  • Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
    Jeong Heo, Yoon Jun Kim, Jin-Woo Lee, Ji Hoon Kim, Young-Suk Lim, Kwang-Hyub Han, Sook-Hyang Jeong, Mong Cho, Ki Tae Yoon, Si Hyun Bae, Eric D. Crown, Linda M. Fredrick, Negar Niki Alami, Armen Asatryan, Do Hyun Kim, Seung Woon Paik, Youn-Jae Lee
    Gut and Liver.2021; 15(6): 895.     CrossRef
  • The Significance of HCV Viral Load in the Incidence of HCC: a Correlation Between Mir-122 and CCL2
    Heba K. Nabih
    Journal of Gastrointestinal Cancer.2020; 51(2): 412.     CrossRef
  • Apolipoprotein E Genotype and Expression Correlated with Hepatitis C Virus Genotype and Infection
    Gyu-Nam Park, Hyun-Jung Jo, Hye-Ran Kim, Min-Ju Kim, Kyung-A Shin, Seung-Bok Hong, Kyung-Soo Chang
    Journal of Bacteriology and Virology.2019; 49(1): 27.     CrossRef
  • Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
    Chen‐Hua Liu, Chun‐Jen Liu, Tung‐Hung Su, Hung‐Chih Yang, Chun‐Ming Hong, Tai‐Chung Tseng, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao
    Journal of Gastroenterology and Hepatology.2018; 33(3): 710.     CrossRef
  • A large healthcare-associated outbreak of hepatitis C virus genotype 1a in a clinic in Korea
    Yoon-Seok Chung, Ju-yeon Choi, Myung Guk Han, Kye Ryeong Park, Su-Jin Park, Hyerim Lee, Youngmee Jee, Chun Kang
    Journal of Clinical Virology.2018; 106: 53.     CrossRef
  • Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
    Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee
    Clinical and Molecular Hepatology.2018; 24(3): 311.     CrossRef
  • High-resolution melting combines with Bayes discriminant analysis: a novel hepatitis C virus genotyping method
    Daxian Wu, Xiaoyu Fu, Ya Wen, Bingjie Liu, Zhongping Deng, Lizhong Dai, Deming Tan
    Clinical and Experimental Medicine.2017; 17(3): 325.     CrossRef
  • Urgency to treat patients with chronic hepatitis C in Asia
    Jia‐Horng Kao, Sang Hoon Ahn, Rong‐Nan Chien, Mong Cho, Wan‐Long Chuang, Sook‐Hyang Jeong, Chen‐Hua Liu, Seung‐Woon Paik
    Journal of Gastroenterology and Hepatology.2017; 32(5): 966.     CrossRef
  • Clinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea
    Ra Ri Cha, Sang Soo Lee, Chang Min Lee, Sung Bok Ji, Hee Cheul Jung, Hyun Chin Cho, Jin Joo Kim, Jae Min Lee, Hong Jun Kim, Chang Yoon Ha, Hyun Jin Kim, Tae-Hyo Kim, Woon Tae Jung, Ok-Jae Lee
    Medicine.2016; 95(6): e2755.     CrossRef
  • A phase 3b study of sofosbuvir plus ribavirin in treatment‐naive and treatment‐experienced Korean patients chronically infected with genotype 2 hepatitis C virus
    S. H. Ahn, Y. S. Lim, K. S. Lee, S. W. Paik, Y. J. Lee, S. H. Jeong, J. H. Kim, S. K. Yoon, H. J. Yim, W. Y. Tak, S. Y. Han, J. C. Yang, H. Mo, A. Mathias, L. Han, S. J. Knox, D. M. Brainard, Y. J. Kim, K. S. Byun, Y. S. Kim, J. Heo, K. H. Han
    Journal of Viral Hepatitis.2016; 23(5): 358.     CrossRef
  • KASL clinical practice guidelines: management of hepatitis C

    Clinical and Molecular Hepatology.2016; 22(1): 76.     CrossRef
  • A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus
    Young-Suk Lim, Sang Hoon Ahn, Kwan Sik Lee, Seung Woon Paik, Youn-Jae Lee, Sook-Hyang Jeong, Ju-Hyun Kim, Seung Kew Yoon, Hyung Joon Yim, Won Young Tak, Sang-Young Han, Jenny C. Yang, Hongmei Mo, Kimberly L. Garrison, Bing Gao, Steven J. Knox, Phillip S.
    Hepatology International.2016; 10(6): 947.     CrossRef
  • Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir
    Dennis Hernandez, Fei Yu, Xin Huang, Stefan Kirov, Saumya Pant, Fiona McPhee
    Advances in Therapy.2016; 33(7): 1169.     CrossRef
  • Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-Related Mortality in Patients with Hepatitis C Virus Infection
    Ran Noh, Doo Hyuck Lee, Byoung Woon Kwon, Yong Hyun Kim, Suk Bae Kim, Il Han Song
    Gastroenterology Research and Practice.2016; 2016: 1.     CrossRef
  • All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study
    Jia‐Horng Kao, Youn‐Jae Lee, Jeong Heo, Sang‐Hoon Ahn, Young‐Suk Lim, Cheng‐Yuan Peng, Ting‐Tsung Chang, Anne Torbeyns, Eric Hughes, Rafia Bhore, Stephanie Noviello
    Liver International.2016; 36(10): 1433.     CrossRef
  • Epidemiology of Hepatitis C Virus Infection in Korea
    Sook-Hyang Jeong
    Korean Journal of Medicine.2015; 88(6): 630.     CrossRef
  • Prospective cohort study on the outcomes of hepatitis C virus‐related cirrhosis in South Korea
    Sang Soo Lee, Sook‐Hyang Jeong, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, Eun Uk Jung, In Hee Kim, Si Hyun Bae, Han Chu Lee, Mee‐Kyung Kee, Chun Kang
    Journal of Gastroenterology and Hepatology.2015; 30(8): 1281.     CrossRef
  • Phylogeny and molecular evolution of the hepatitis C virus
    Paulina Jackowiak, Karolina Kuls, Lucyna Budzko, Anna Mania, Magdalena Figlerowicz, Marek Figlerowicz
    Infection, Genetics and Evolution.2014; 21: 67.     CrossRef
  • KASL clinical practice guidelines: Management of Hepatitis C

    Clinical and Molecular Hepatology.2014; 20(2): 89.     CrossRef
  • Impact of New Hepatitis C Treatments in Different Regions of the World
    Lai Wei, Anna S.F. Lok
    Gastroenterology.2014; 146(5): 1145.     CrossRef
  • 12,256 View
  • 65 Download
  • Crossref